Safety Results Prompt Bristol To Refine Apixaban Dosing In Acute Coronary Syndrome Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm is discussing Phase III design with regulators.
You may also be interested in...
Oral Anticoagulants Market Snapshot: Big Bucks, But Payers Are On Guard
Pradaxa, the Boehringer Ingelheim drug that FDA approved on Oct. 19, is the first of several oral anti-coagulants that could come on the U.S. market near-term and shake up existing standards of care.
Oral Anticoagulants Market Snapshot: Big Bucks, But Payers Are On Guard
Pradaxa, the Boehringer Ingelheim drug that FDA approved on Oct. 19, is the first of several oral anti-coagulants that could come on the U.S. market near-term and shake up existing standards of care.
Portola Anticipates "Best In Class" Status For Oral Anticoagulant Betrixaban
Portola Pharmaceuticals is launching a 500-patient Phase II safety and efficacy trial for its novel oral Factor Xa inhibitor anticoagulant betrixaban, touting the compound's potential for three significant areas of differentiation from other late-stage candidates in the crowded anti-thrombotic class